Abstracts tagged "Colchicine"

Abstract Number: 046 • 2023 Pediatric Rheumatology Symposium
Colchicine Adherence Among Children and Young Adults with Familial Mediterranean Fever During Treatment with interleukin-1 Inhibitors
Yoel Levinsky¹, rotem tal², Liora Harel³ and Gil Amarilyo⁴, ¹Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ²Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ³Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ⁴Schneider Children's Medical Center of Israel, Petach Tikva, Israel
Background/Purpose: IL-1 inhibitor are approved for familial Mediterranean fever (FMF) patients who are resistant to colchicine. However, it is imperative to continue concomitant treatment with…
Abstract Number: 053 • 2023 Pediatric Rheumatology Symposium
Can Children with Colchicine Resistant FMF Be Treated with on Demand Canakinumab Regimen?– a Multicenter Study
Katy shehadeh¹, Yoel Levinsky², rotem tal³, Neta Hana Aviran³, Yonatan Butbul Aviel⁴, Irit Tirosh⁵, Shelly Kagan⁶, Tarek Zoabi³, Shiri Spielman⁷, Adi Miller-Barmak⁴, Rotem Semo Oz⁸, Liora Harel⁹, Gabriel Chodick¹⁰ and Gil Amarilyo⁶, ¹Tel Aviv University, Tel Aviv, Israel, ²Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁴Rambam Medical center, Haifa, Israel, ⁵Sheba Medical Center, Savyon, Israel, ⁶Schneider Children's Medical Center of Israel, Petach Tikva, Israel, ⁷Sheba Tel-HaShomer Medical Center, Givataim, Israel, ⁸Sheba medical center, Herzelyia, Israel, ⁹Scheiders Children Medical Center of Israel, Petah-Tiqva, Israel, ¹⁰Maccabitech institute for research and innovation, Maccabi healthcare services, Tel Aviv, Israel
Background/Purpose: Familial Mediterranean fever (FMF) is the most common autoinflammatory disease. Without therapy, it may lead to the development of secondary amyloidosis. Treatment with colchicine…
Abstract Number: 328 • 2019 ACR/ARP Annual Meeting
Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events
Sarah Stewart¹, Kevin Yang ², Kate Atkins ², Nicola Dalbeth ² and Philip Robinson ³, ¹University of Auckland, Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³The University of Queensland, Brisbane, Australia
Background/Purpose: Colchicine is a widely used drug used to treat rheumatic and inflammatory conditions. Due to its long historical use in medicine, controlled clinical trials…
Abstract Number: 360 • 2019 ACR/ARP Annual Meeting
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Philip Robinson¹, Nicola Dalbeth ² and Peter Donovan ³, ¹University of Queensland, Brisbane, Queensland, Australia, ²University of Auckland, Auckland, New Zealand, ³University of Queensland, HERSTON, Australia
Background/Purpose: Prophylaxis of acute gout flares when commencing urate lowering therapy is recommended by international guidelines. Whether this is a cost-effective intervention is currently unknown.…
Abstract Number: 1268 • 2019 ACR/ARP Annual Meeting
Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?
Hakan Emmungil¹, Ufuk İlgen ¹, Sezin Turan ¹, Samet Yaman ² and Orhan Küçükşahin ³, ¹Trakya University, Edirne, Turkey, ²Yıldırım Beyazıt University, Ankara, Turkey, ³Liv Hospital, Ankara, Turkey
Background/Purpose: Colchicine is the mainstay of treatment for prevention of attacks and associated amyloidosis in Familial Mediterranean Fever (FMF). Two approved colchicine preparations are currently…
Abstract Number: 1276 • 2018 ACR/ARHP Annual Meeting
Effect of Colchicine on Diabetes Incidence Among Gout Patients in a Veterans’ Affairs Population
Anastasia Slobodnick¹, Virginia Pike², Michael Toprover¹ and Michael Pillinger¹, ¹Medicine/Rheumatology, NYU School of Medicine, New York, NY, ²Medicine/Rheumatology, New York Harbor VA Healthcare System, New York, NY
Background/Purpose: Previous studies suggest that patients with gout are at increased risk for developing diabetes.1 One possible explanation for this increased risk is the activation…
Abstract Number: 1321 • 2018 ACR/ARHP Annual Meeting
Clinical and Genetic Analysis of the Patients Mimicking Familial Mediterranean Fever
Dai Kishida¹, Yasuhiro Shimojima² and Yoshiki Sekijima¹, ¹Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ²Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Clinical and genetic analysis of the patients mimicking familial Mediterranean feverBackground/Purpose: Familial Mediterranean fever (FMF) is an auto-inflammatory disease characterized by recurrent episodes of fever…
Abstract Number: 2968 • 2018 ACR/ARHP Annual Meeting
Role of Choline in Gouty Inflammation
Elsa Sanchez-Lopez¹, Zhenyu Zhong¹, Alex Stubelius², Shannon R Sweeney³, Ru Liu-Bryan^4,5, Juan Carlos Lacal⁶, Stefano Tiziani^3,7,8, Robert Terkeltaub^4,9, Monica Guma⁹ and Michael Karin¹, ¹Department of Pharmacology, School of Medicine. UCSD., La Jolla, CA, ²Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ³Department of Nutritional Sciences. The University of Texas at Austin., Austin, TX, ⁴VA San Diego Healthcare System, San Diego, CA, ⁵Medicine-Rheumatology, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA, ⁶Translational Oncology. Department of Oncology, Hospital Universitario Fuenlabrada, Madrid, Spain, ⁷Department of Molecular Biosciences, College of Natural Sciences. The University of Texas at Austin., Austin, TX, ⁸Department of Pediatrics, Dell Medical School. The University of Texas at Austin., Austin, TX, ⁹Medicine, Division of Rheumatology, Allergy and Immunology. UCSD., La Jolla, CA
Background/Purpose: Gout is characterized by deposition of monosodium urate (MSU) crystals in articular joints, where they activate macrophages inducing NLRP3 inflammasome activation and bioactive IL-1β…
Abstract Number: 368 • 2017 ACR/ARHP Annual Meeting
Evaluation of Efficacy and Safety of Opocalcium Colchicine, and Anti-IL1 Treatment in Childhood Colchicine-Resistant Familial Mediterranean Fever
Kenan Barut, Amra Adrovic, Sezgin Sahin, Asli Kaplan and Ozgur Kasapcopur, Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: The colchicine-resistant FMF (crFMF) is defined as 6 or more polyserositis attacks in the last year despite the regular usage of colchicine in the…
Abstract Number: 1144 • 2017 ACR/ARHP Annual Meeting
Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Yu Guo⁴, Stuart Katz⁵, Binita Shah⁵, Irina Dektiarev⁵, Svetlana Krasnokutsky Samuels² and Michael Pillinger², ¹Medicine, Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, New York University School of Medicine, New York, NY, ³Medicine/Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁴Population Health/Statistics, New York University School of Medicine, New York, NY, ⁵Medicine/Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: We have previously reported that patients with gout have impaired vascular endothelial and smooth muscle responsiveness, but whether initiating appropriate gout therapy ameliorates these…
Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting
Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)
Dolores Ramos-Bello¹, Crisol Alvarez-Quiroga², Georgina Aguilera Barragán-Pickens³, Angel Javier Pedro Martínez³, Tania Adriana Luna-Zúñiga³, Georgina Martínez-Flores³, Eduardo Saul Acevedo-Castañeda⁴, Homero López-Ferretis³, Enrique Cuevas-Orta³, Eva Santillan-Guerrero³, Ricardo Moreno-Valdez³, Martín Saldaña-Baarnard³, Marco Ulises Martinez-Martinez⁵, David Herrera Van Oostdam⁶, Roberto González-Amaro⁷ and Carlos Abud-Mendoza⁸, ¹Reumatología, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosi, Mexico, ²División de Medicina Molecular y Traslacional, Centro de Investigación en Ciencias de la Salud y Biomedicina, UASLP, San Luis Potosí, Mexico, ³Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁴Medicina Interna, Unidad Regional de Reumatologia y Osteoporosis Hospital Central "Dr. Ignacio Morones Prieto" y Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁵Unidad de Investigaciones Reumatológicas, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico, ⁶Unidad de Investigaciones Reumatológicas, Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, ⁷Inmunología, Facultad de Medicina de la UASLP, San Luis Potosí, Mexico, ⁸Unidad de Investigaciones Reumatológicas y Osteoporosis, Faculty of Medicine, Universidad Autónoma de San Luis Potosí and Hospital Central, San Luis Potosí, Mexico
Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…
Abstract Number: 79 • 2017 Pediatric Rheumatology Symposium
Predicting Colchicine Response in Patients with Undefined Autoinflammatory Diseases
Jonathan S. Hausmann^1,2, Burcu Guven², Edwin Anderson³ and Fatma Dedeoglu², ¹Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ²Rheumatology, Boston Children's Hospital, Boston, MA, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Autoinflammatory diseases (AIDs) are a rare group of illnesses characterized by unprovoked episodes of fever and systemic inflammation. An understanding of their pathophysiology has…
Abstract Number: 230 • 2016 ACR/ARHP Annual Meeting
A Survey of Knowledge of Optimal Gout Management in an Academic Primary Care Setting
Stefanie Wade¹ and Micha Abeles², ¹Medicine, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, Consulting Rheumatologist, Midstate Medical Center, Meriden, CT
Background/Purpose: We reviewed previous treatment approaches for gout in patients referred to a university rheumatology practice for gout management. All patients met the 2015 American…
Abstract Number: 1013 • 2016 ACR/ARHP Annual Meeting
The Risk of Colchicine Associated Myopathy in Gout: Influence of Concomitant Use of Statin
Oh Chan Kwon¹, Byeongzu Ghang², Seokchan Hong³, Yong-Gil Kim⁴, Chang-Keun Lee³ and Bin Yoo⁴, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan Collage of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: To investigate the risk of concomitant use of statin on the development of myopathy in gout patients who received colchicine. Methods: We included patients…
Abstract Number: 2971 • 2016 ACR/ARHP Annual Meeting
Characteristics and Management of IgA Vasculitis (Henoch-Schönlein purpura) in Adults: Data from the 260 Patients Included in the Igavas Survey
Alexandra Audemard-Verger¹, Evangeline Pillebout², Agnès Dechartres³, Johan Chanal⁴, Zahir Amoura⁵, Noemie Le Gouellec⁶, Patrice Cacoub⁷, Noémie Jourde-Chiche⁸, Geoffroy Urbanski⁹, Jean-Francois Augusto⁹, Guillaume Moulis¹⁰, Loic Raffray¹¹, Alban Deroux¹², Aurélie Hummel¹³, Bertrand Lioger¹⁴, Melanie Catroux¹⁵, Stanislas Faguer¹⁶, Julie Goutte¹⁷, Nihal Martis¹⁸, Francois Maurier¹⁹, Etienne Riviere²⁰, Sébastien Sanges²¹, Aurélie Baldolli²², Nathalie Costedoat-Chalumeau²³, Melanie Roriz²⁴, Xavier Puéchal²⁵, Marc Andre²⁶, Christian Lavigne²⁷, Boris Bienvenu²⁸, Arsène Mékinian²⁹, Elie Zagdoun³⁰, Charlotte Girard³¹, Alice Berezne³², Loïc Guillevin²⁵, Eric Thervet³³ and Benjamin Terrier³⁴, ¹Internal Medicine, Caen, France, ²Nephrology, Saint Louis, Paris, France, ³Epidemiology, Hotel Dieu, Paris, France, ⁴Dermatology, Cochin Hospital, Paris, France, ⁵Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁶Internal Medicine, Lille, France, ⁷Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, Département de Médecine Interne et d’Immunologie clinique, DHU i2B, Inflammation, Immunopathologie, Biothérapie, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ⁸Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ⁹Internal Medicine, CHU, Angers, France, ¹⁰CHU Purpan, Toulouse, France, ¹¹Internal Medicine, CHU de Bordeaux, Bordeaux, France, ¹²Internal Medicine, CHU Grenoble, Grenoble, France, ¹³Necker, paris, France, ¹⁴GICC UMR 7292, University François Rabelais, Tours, France, ¹⁵Internal Medicine, Cochin Hospital, Paris, France, ¹⁶Nephrology, CHU, Toulouse, France, ¹⁷Internal Medicine, CHU, Paris, France, ¹⁸Internal Medicine, CHU, Nice, France, ¹⁹Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, ²⁰Internal Medicine, CHU, Bordeaux, France, ²¹Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, ²²Internal Medicine, CHU, Caen, France, ²³Internal Medicine, Cochin University Hospital, Paris, France, ²⁴internal Medicine, Lariboisière, Paris, France, ²⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²⁶Internal Medicine CHU G Montpied, Internal Medicine, Clermont Ferrand, France, ²⁷CHU Angers, department of Internal Medicine, Angers, France, ²⁸Caen University Hospital, Caen, France, ²⁹Service de médecine interne. Hôpital Saint-Antoine., Paris, France, ³⁰Internal Medicine, CH, Saint-Lo, France, ³¹Internal Medicine, CHU, Lyon, France, ³²Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ³³Nephrology, Hopital Européen Georges Pompidou, APHP, PARIS, France, ³⁴National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: We analyzed data from 260 patients with IgAV included in a French multicenter retrospective IGAVAS survey. Results: Mean age at diagnosis was 50.1±18 years,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].